254 related articles for article (PubMed ID: 34592318)
1. Study of Alteplase for Respiratory Failure in SARS-CoV-2 COVID-19: A Vanguard Multicenter, Rapidly Adaptive, Pragmatic, Randomized Controlled Trial.
Barrett CD; Moore HB; Moore EE; Wang J; Hajizadeh N; Biffl WL; Lottenberg L; Patel PR; Truitt MS; McIntyre RC; Bull TM; Ammons LA; Ghasabyan A; Chandler J; Douglas IS; Schmidt EP; Moore PK; Wright FL; Ramdeo R; Borrego R; Rueda M; Dhupa A; McCaul DS; Dandan T; Sarkar PK; Khan B; Sreevidya C; McDaniel C; Grossman Verner HM; Pearcy C; Anez-Bustillos L; Baedorf-Kassis EN; Jhunjhunwala R; Shaefi S; Capers K; Banner-Goodspeed V; Talmor DS; Sauaia A; Yaffe MB
Chest; 2022 Mar; 161(3):710-727. PubMed ID: 34592318
[TBL] [Abstract][Full Text] [Related]
2. Sargramostim to treat patients with acute hypoxic respiratory failure due to COVID-19 (SARPAC): A structured summary of a study protocol for a randomised controlled trial.
Bosteels C; Maes B; Van Damme K; De Leeuw E; Declercq J; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
Trials; 2020 Jun; 21(1):491. PubMed ID: 32503663
[TBL] [Abstract][Full Text] [Related]
3. Early outcomes with utilization of tissue plasminogen activator in COVID-19-associated respiratory distress: A series of five cases.
Christie DB; Nemec HM; Scott AM; Buchanan JT; Franklin CM; Ahmed A; Khan MS; Callender CW; James EA; Christie AB; Ashley DW
J Trauma Acute Care Surg; 2020 Sep; 89(3):448-452. PubMed ID: 32427774
[TBL] [Abstract][Full Text] [Related]
4. Study of alteplase for respiratory failure in severe acute respiratory syndrome coronavirus 2/COVID-19: Study design of the phase IIa STARS trial.
Moore HB; Barrett CD; Moore EE; Jhunjhunwala R; McIntyre RC; Moore PK; Wang J; Hajizadeh N; Talmor DS; Sauaia A; Yaffe MB
Res Pract Thromb Haemost; 2020 Aug; 4(6):984-996. PubMed ID: 32838109
[TBL] [Abstract][Full Text] [Related]
5. MUlticenter STudy of tissue plasminogen activator (alteplase) use in COVID-19 severe respiratory failure (MUST COVID): A retrospective cohort study.
Barrett CD; Moore HB; Moore EE; Benjamin Christie D; Orfanos S; Anez-Bustillos L; Jhunjhunwala R; Hussain S; Shaefi S; Wang J; Hajizadeh N; Baedorf-Kassis EN; Al-Shammaa A; Capers K; Banner-Goodspeed V; Wright FL; Bull T; Moore PK; Nemec H; Thomas Buchanan J; Nonnemacher C; Rajcooar N; Ramdeo R; Yacoub M; Guevara A; Espinal A; Hattar L; Moraco A; McIntyre R; Talmor DS; Sauaia A; Yaffe MB
Res Pract Thromb Haemost; 2022 Feb; 6(2):e12669. PubMed ID: 35341072
[TBL] [Abstract][Full Text] [Related]
6. Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): A case series.
Wang J; Hajizadeh N; Moore EE; McIntyre RC; Moore PK; Veress LA; Yaffe MB; Moore HB; Barrett CD
J Thromb Haemost; 2020 Jul; 18(7):1752-1755. PubMed ID: 32267998
[TBL] [Abstract][Full Text] [Related]
7. Salvage use of tissue plasminogen activator (tPA) in the setting of acute respiratory distress syndrome (ARDS) due to COVID-19 in the USA: a Markov decision analysis.
Choudhury R; Barrett CD; Moore HB; Moore EE; McIntyre RC; Moore PK; Talmor DS; Nydam TL; Yaffe MB
World J Emerg Surg; 2020 Apr; 15(1):29. PubMed ID: 32312290
[TBL] [Abstract][Full Text] [Related]
8. Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia: A Randomized Clinical Trial.
Menichetti F; Popoli P; Puopolo M; Spila Alegiani S; Tiseo G; Bartoloni A; De Socio GV; Luchi S; Blanc P; Puoti M; Toschi E; Massari M; Palmisano L; Marano G; Chiamenti M; Martinelli L; Franchi S; Pallotto C; Suardi LR; Luciani Pasqua B; Merli M; Fabiani P; Bertolucci L; Borchi B; Modica S; Moneta S; Marchetti G; d'Arminio Monforte A; Stoppini L; Ferracchiato N; Piconi S; Fabbri C; Beccastrini E; Saccardi R; Giacometti A; Esperti S; Pierotti P; Bernini L; Bianco C; Benedetti S; Lanzi A; Bonfanti P; Massari M; Sani S; Saracino A; Castagna A; Trabace L; Lanza M; Focosi D; Mazzoni A; Pistello M; Falcone M;
JAMA Netw Open; 2021 Nov; 4(11):e2136246. PubMed ID: 34842924
[TBL] [Abstract][Full Text] [Related]
9. Responsiveness of Inhaled Epoprostenol in Respiratory Failure due to COVID-19.
Sonti R; Pike CW; Cobb N
J Intensive Care Med; 2021 Mar; 36(3):327-333. PubMed ID: 33234007
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Intravenous Tenecteplase Bolus in Acute Ischemic Stroke: Results of Two Open-Label, Multicenter Trials.
Ramakrishnan TCR; Kumaravelu S; Narayan SK; Buddha SS; Murali C; Majeed PHA; Meenakshi-Sundaram S; Wadia RS; Sharma V; Basu I; Vijaya P; Salam KA; Barmare S; Vaid Z; Nirmal Raj KK; Wattamwar PR; Asokan K; Dhonge V; Nellikunja S; Namjoshi D; Srinivasa R; Laddhad DS; Deshpande SD; Raghunath B; Kalita J; Kumar M; Misra UK; Pradeep M;
Am J Cardiovasc Drugs; 2018 Oct; 18(5):387-395. PubMed ID: 29948822
[TBL] [Abstract][Full Text] [Related]
11. Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration in COVID-19 (REALIST-COVID-19): A structured summary of a study protocol for a randomised, controlled trial.
Gorman E; Shankar-Hari M; Hopkins P; Tunnicliffe WS; Perkins GD; Silversides J; McGuigan P; Jackson C; Boyle R; McFerran J; McDowell C; Campbell C; McFarland M; Smythe J; Thompson J; Williams B; Curley G; Laffey JG; Clarke M; O'Kane C; McAuley DF
Trials; 2020 Jun; 21(1):462. PubMed ID: 32493473
[TBL] [Abstract][Full Text] [Related]
12. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy.
Grasselli G; Zangrillo A; Zanella A; Antonelli M; Cabrini L; Castelli A; Cereda D; Coluccello A; Foti G; Fumagalli R; Iotti G; Latronico N; Lorini L; Merler S; Natalini G; Piatti A; Ranieri MV; Scandroglio AM; Storti E; Cecconi M; Pesenti A;
JAMA; 2020 Apr; 323(16):1574-1581. PubMed ID: 32250385
[TBL] [Abstract][Full Text] [Related]
13. Effect of Helmet Noninvasive Ventilation vs High-Flow Nasal Oxygen on Days Free of Respiratory Support in Patients With COVID-19 and Moderate to Severe Hypoxemic Respiratory Failure: The HENIVOT Randomized Clinical Trial.
Grieco DL; Menga LS; Cesarano M; Rosà T; Spadaro S; Bitondo MM; Montomoli J; Falò G; Tonetti T; Cutuli SL; Pintaudi G; Tanzarella ES; Piervincenzi E; Bongiovanni F; Dell'Anna AM; Delle Cese L; Berardi C; Carelli S; Bocci MG; Montini L; Bello G; Natalini D; De Pascale G; Velardo M; Volta CA; Ranieri VM; Conti G; Maggiore SM; Antonelli M;
JAMA; 2021 May; 325(17):1731-1743. PubMed ID: 33764378
[TBL] [Abstract][Full Text] [Related]
14. Defibrotide Therapy for SARS-CoV-2 ARDS.
Frame D; Scappaticci GB; Braun TM; Maliarik M; Sisson TH; Pipe SW; Lawrence DA; Richardson PG; Holinstat M; Hyzy RC; Kaul DR; Gregg KS; Lama VN; Yanik GA
Chest; 2022 Aug; 162(2):346-355. PubMed ID: 35413279
[TBL] [Abstract][Full Text] [Related]
15. Response to the first awake prone positioning relates with intubation rate in SARS-CoV-2 patients suffering from acute respiratory failure with moderate to severe hypoxaemia: a retrospective study.
Lupieri E; Boffi A; Ltaief Z; Schneider A; Abed-Maillard S; Chiche JD; Oddo M; Piquilloud L
Swiss Med Wkly; 2022 Aug; 152():w30212. PubMed ID: 36102065
[TBL] [Abstract][Full Text] [Related]
16. Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage.
Giugliano RP; McCabe CH; Antman EM; Cannon CP; Van de Werf F; Wilcox RG; Braunwald E;
Am Heart J; 2001 May; 141(5):742-50. PubMed ID: 11320361
[TBL] [Abstract][Full Text] [Related]
17. A pilot study of therapeutic plasma exchange for serious SARS CoV-2 disease (COVID-19): A structured summary of a randomized controlled trial study protocol.
Faqihi F; Alharthy A; Alodat M; Asad D; Aletreby W; Kutsogiannis DJ; Brindley PG; Karakitsos D
Trials; 2020 Jun; 21(1):506. PubMed ID: 32513290
[TBL] [Abstract][Full Text] [Related]
18. High-Dose Inhaled Nitric Oxide in Acute Hypoxemic Respiratory Failure Due to COVID-19: A Multicenter Phase II Trial.
Di Fenza R; Shetty NS; Gianni S; Parcha V; Giammatteo V; Safaee Fakhr B; Tornberg D; Wall O; Harbut P; Lai PS; Li JZ; Paganoni S; Cenci S; Mueller AL; Houle TT; Akeju O; Bittner EA; Bose S; Scott LK; Carroll RW; Ichinose F; Hedenstierna M; Arora P; Berra L;
Am J Respir Crit Care Med; 2023 Dec; 208(12):1293-1304. PubMed ID: 37774011
[No Abstract] [Full Text] [Related]
19. Senicapoc treatment in COVID-19 patients with severe respiratory insufficiency-A randomized, open-label, phase II trial.
Granfeldt A; Andersen LW; Vallentin MF; Hilberg O; Hasselstrøm JB; Sørensen LK; Mogensen S; Christensen S; Grejs AM; Rasmussen BS; Kristiansen KT; Strøm T; Johansen IS; Schjørring OL; Simonsen U
Acta Anaesthesiol Scand; 2022 Aug; 66(7):838-846. PubMed ID: 35403225
[TBL] [Abstract][Full Text] [Related]
20. Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19.
Whyte CS; Morrow GB; Mitchell JL; Chowdary P; Mutch NJ
J Thromb Haemost; 2020 Jul; 18(7):1548-1555. PubMed ID: 32329246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
